Total Payments
$552,004
2024 Payments
$27,309
Companies
31
Transactions
945
Medicare Patients
2,253
Medicare Billing
$234,065
Payment Breakdown by Category
Other$314,238 (56.9%)
Research$194,129 (35.2%)
Food & Beverage$20,452 (3.7%)
Consulting$13,500 (2.4%)
Travel$9,629 (1.7%)
Education$55.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $303,288 | 129 | 54.9% |
| Unspecified | $194,129 | 18 | 35.2% |
| Food and Beverage | $20,452 | 748 | 3.7% |
| Consulting Fee | $13,500 | 5 | 2.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,950 | 13 | 2.0% |
| Travel and Lodging | $9,629 | 26 | 1.7% |
| Education | $55.92 | 6 | 0.0% |
Payments by Type
General
$357,875
927 transactions
Research
$194,129
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $194,611 | 20 | $0 (2023) |
| ABBVIE INC. | $170,606 | 410 | $0 (2024) |
| Allergan, Inc. | $135,265 | 287 | $0 (2022) |
| Biohaven Pharmaceuticals, Inc. | $21,102 | 43 | $0 (2021) |
| Eisai Inc. | $19,281 | 34 | $0 (2024) |
| Biohaven Pharmaceutical Holding Company Ltd. | $6,147 | 19 | $0 (2022) |
| PFIZER INC. | $788.56 | 61 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $617.79 | 5 | $0 (2021) |
| SK Life Science, Inc. | $488.84 | 8 | $0 (2023) |
| Biogen, Inc. | $441.41 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27,309 | 163 | ABBVIE INC. ($14,918) |
| 2023 | $48,247 | 155 | ABBVIE INC. ($38,392) |
| 2022 | $71,150 | 150 | ABBVIE INC. ($54,558) |
| 2021 | $114,831 | 218 | AbbVie Inc. ($62,737) |
| 2020 | $38,531 | 114 | Allergan, Inc. ($32,351) |
| 2019 | $83,207 | 71 | Eli Lilly and Company ($42,445) |
| 2018 | $145,635 | 30 | Eli Lilly and Company ($134,243) |
| 2017 | $23,094 | 44 | Allergan Inc. ($17,441) |
All Payment Transactions
945 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $12.75 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/12/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $8.00 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/11/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: NEUROSCIENCE | ||||||
| 12/06/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: Neurology | ||||||
| 12/06/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $6.57 | General |
| Category: PAIN | ||||||
| 12/05/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/04/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: Neuropsychiatry | ||||||
| 12/04/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $11.70 | General |
| Category: NEUROSCIENCE | ||||||
| 12/04/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $8.06 | General |
| Category: PAIN | ||||||
| 12/04/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $7.04 | General |
| Category: Neuropsychiatry | ||||||
| 11/22/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $5.58 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: Neuropsychiatry | ||||||
| 11/21/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $10.84 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,675.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $6.61 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/14/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,095.00 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $912.50 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $36.96 | General |
| Category: Neurology | ||||||
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $8.89 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/07/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $9.95 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/06/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $912.50 | General |
| Category: Neurology | ||||||
| 11/06/2024 | Eisai Inc. | Leqembi (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $365.00 | General |
| Category: Neurology | ||||||
| 10/31/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.85 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $8.30 | General |
| Category: BOTOX THERAPEUTIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | Eli Lilly and Company | $91,289 | 6 |
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $69,011 | 3 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $26,365 | 4 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $5,374 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $1,239 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $355.00 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $300.00 | 1 |
| A 24-MONTH, PHASE 3, MULTICENTER, PLACEBO-CONTROLLED STUDY OF EFFICACY AND SAFETY OF SOLANEZUMAB VERSUS PLACEBO IN PRODROMAL ALZHEIMERS DISEASE | Eli Lilly and Company | $195.90 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 549 | 728 | $194,336 | $55,717 |
| 2022 | 10 | 495 | 693 | $151,473 | $52,182 |
| 2021 | 11 | 589 | 823 | $172,061 | $63,801 |
| 2020 | 12 | 620 | 905 | $164,508 | $62,364 |
Total Patients
2,253
Total Services
3,149
Medicare Billing
$234,065
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 120 | 209 | $33,440 | $12,453 | 37.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 61 | 61 | $27,145 | $8,138 | 30.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 92 | 117 | $22,804 | $7,269 | 31.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 68 | 70 | $20,918 | $7,012 | 33.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 46 | 59 | $18,734 | $6,023 | 32.1% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Facility | 2023 | 18 | 48 | $15,432 | $4,032 | 26.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 85 | 91 | $33,215 | $3,754 | 11.3% |
| G0508 | Telehealth consultation, critical care, initial , physicians typically spend 60 minutes communicating with the patient and providers via telehealth | Office | 2023 | 20 | 20 | $10,500 | $3,192 | 30.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 19 | 19 | $8,408 | $2,592 | 30.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 20 | 34 | $3,740 | $1,253 | 33.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 115 | 164 | $23,000 | $11,272 | 49.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 73 | 75 | $33,375 | $10,886 | 32.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 89 | 174 | $27,840 | $9,670 | 34.7% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Facility | 2022 | 24 | 66 | $10,402 | $5,402 | 51.9% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 84 | 85 | $31,025 | $3,776 | 12.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 28 | 32 | $6,570 | $3,443 | 52.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $5,625 | $2,884 | 51.3% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 30 | 32 | $6,688 | $2,505 | 37.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 19 | $5,700 | $2,006 | 35.2% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Facility | 2022 | 13 | 26 | $1,248 | $338.96 | 27.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 89 | 89 | $38,570 | $13,827 | 35.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 116 | 210 | $33,140 | $11,891 | 35.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 127 | 173 | $24,357 | $11,845 | 48.6% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Facility | 2021 | 28 | 83 | $12,351 | $7,594 | 61.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 42 | 52 | $10,120 | $5,749 | 56.8% |
About Dr. Siddharth Kaul, MD
Dr. Siddharth Kaul, MD is a Neurology healthcare provider based in Bridgeton, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/08/2008. The National Provider Identifier (NPI) number assigned to this provider is 1245493402.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Siddharth Kaul, MD has received a total of $552,004 in payments from pharmaceutical and medical device companies, with $27,309 received in 2024. These payments were reported across 945 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($303,288).
As a Medicare-enrolled provider, Kaul has provided services to 2,253 Medicare beneficiaries, totaling 3,149 services with total Medicare billing of $234,065. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Neurology
- Location Bridgeton, MO
- Active Since 07/08/2008
- Last Updated 11/25/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1245493402
Products in Payments
- UBRELVY (Drug) $132,914
- BOTOX (Biological) $95,057
- BOTOX (Drug) $39,703
- QULIPTA (Drug) $31,869
- NURTEC ODT (Drug) $27,930
- Leqembi (Drug) $18,668
- BOTOX CHRONIC MIGRAINE (Drug) $6,228
- ZEPOSIA (Drug) $537.62
- Fycompa (Drug) $509.94
- APTIOM (Drug) $432.49
- Soliris (Drug) $369.56
- XCOPRI (Drug) $363.91
- INGREZZA (Drug) $295.93
- SOLIRIS (Drug) $248.23
- OCREVUS (Biological) $247.42
- TECFIDERA (Drug) $156.02
- REXULTI (Drug) $149.99
- ADUHELM (Biological) $141.85
- BRIUMVI (Drug) $135.98
- Epidiolex (Drug) $126.21
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Bridgeton
Dr. Daniel Mattson, Md, MD
Neurology — Payments: $500,463
Neurology $500,463
Dr. Seth Hepner, Md, MD
Neurology — Payments: $251,257
Neurology $251,257
Dr. Xinrong Lu, M.d, M.D
Neurology — Payments: $22,610
Neurology $22,610
Dr. Amer Alshekhlee, Md, MD
Neurology — Payments: $14,239
Neurology $14,239
Dr. Chizoba Ezepue, Md, MD
Neurology — Payments: $5,505
Neurology $5,505
Dr. Robert Margolis, M.d, M.D
Neurology — Payments: $3,305
Neurology $3,305